Nemoda Zsofia, Angyal Nora, Tarnok Zsanett, Birkas Emma, Bognar Emese, Sasvari-Szekely Maria, Gervai Judit, Lakatos Krisztina
Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary.
Vadaskert Child and Adolescent Psychiatric Clinic, Budapest, Hungary.
Front Neurosci. 2019 Jan 14;12:1051. doi: 10.3389/fnins.2018.01051. eCollection 2018.
Among the monoaminergic modulatory neurotransmitters, norepinephrine is involved in task orienting, hence noradrenergic genetic variants have been studied in connection to attentional processes. The role of this catecholamine system is also highlighted by the selective norepinephrine transporter blocking atomoxetine, which has proved to be effective in the pharmacological treatment of Attention Deficit Hyperactivity Disorder (ADHD). In the present genetic association study three single nucleotide polymorphisms (rs28386840, rs2242446, rs3785143 SNPs) were analyzed from the 5' region of the norepinephrine transporter (, ) gene, which have been linked to ADHD previously. Attention problems scores of the mother-rated Child Behavior Checklist (CBCL) were used in separate analyses of 88 preschoolers (59.1% male, 6 years of age) recruited from the general population and 120 child psychiatry patients with ADHD diagnosis (85.8% male, age: 9.8 ± 2.9). The SNPs showed associations with attention problems, but the direction was different in the two groups. Regarding the promoter variant rs28386840, which showed the most consistent association, the T-allele-carrier patients with ADHD had lower CBCL attention problems scores compared to patients with AA genotype ( = 0.023), whereas T-allele-carriers in the community sample had more attention problems ( = 0.042). Based on previous reports of lower NE levels in ADHD children and the inverted-U shape effect of NE on cognitive functions, we propose that rs28386840 (-3081) T-allele, which is associated with lower NET expression (and potentially higher synaptic NE level) would support attention processes among ADHD patients (similarly as atomoxetine increases NE levels), whereas it would hinder cortical functions in healthy children.
在单胺能调节性神经递质中,去甲肾上腺素参与任务导向,因此去甲肾上腺素能基因变异已与注意力过程相关联进行研究。选择性去甲肾上腺素转运体阻滞剂托莫西汀也突出了这种儿茶酚胺系统的作用,托莫西汀已被证明在注意力缺陷多动障碍(ADHD)的药物治疗中有效。在本基因关联研究中,对去甲肾上腺素转运体( )基因5'区域的三个单核苷酸多态性(rs28386840、rs2242446、rs3785143 SNPs)进行了分析,这些多态性先前已与ADHD相关联。母亲评定的儿童行为检查表(CBCL)中的注意力问题得分被用于对从普通人群中招募的88名学龄前儿童(59.1%为男性,6岁)和120名诊断为ADHD的儿童精神病患者(85.8%为男性,年龄:9.8±2.9)进行单独分析。这些单核苷酸多态性与注意力问题存在关联,但两组中的方向不同。关于显示出最一致关联的启动子变异rs28386840,与AA基因型患者相比,携带T等位基因的ADHD患者CBCL注意力问题得分更低( = 0.023),而社区样本中的T等位基因携带者有更多注意力问题( = 0.042)。基于先前关于ADHD儿童中去甲肾上腺素水平较低的报道以及去甲肾上腺素对认知功能的倒U形效应,我们提出与较低去甲肾上腺素转运体(NET)表达相关联(并可能具有较高的突触去甲肾上腺素水平)的rs28386840(-3081)T等位基因将支持ADHD患者的注意力过程(类似于托莫西汀增加去甲肾上腺素水平),而它会阻碍健康儿童的皮质功能。